HCC1806 Cells

The HCC1806 cell line is derived from the mammary gland of a 60-year-old patient with acantholytic squamous cell carcinoma. These cells lack receptors for estrogen and progesterone, and the absence of epidermal growth factor receptor (EGFR) amplification, categorize it as a triple-negative breast cancer. The cell line is instrumental for the biological validation of therapeutic targets, as it closely mirrors the behavior of TNBC in vivo, including tendencies for spontaneous metastasis and resistance to conventional therapies like paclitaxel.
Molecular effects of interventions, such as AEB071 treatment, on HCC1806 cells, provide insights into the cell proliferation pathways and the potential of protein kinase inhibitors as therapeutic agents. The use of HCC1806 in xenograft models contributes to the study of tumor growth and metastasis in a controlled environment.
HCC1806 breast cancer cells serve as a valuable tool for the study of breast cancer, particularly within the context of triple-negative subtypes. It stands as a critical resource for researchers looking to unravel the molecular interactions in breast cancer and search for effective treatments against this challenging variant of the disease.